NO20100300L - DHEA-preparater for behandling av menopausen - Google Patents

DHEA-preparater for behandling av menopausen

Info

Publication number
NO20100300L
NO20100300L NO20100300A NO20100300A NO20100300L NO 20100300 L NO20100300 L NO 20100300L NO 20100300 A NO20100300 A NO 20100300A NO 20100300 A NO20100300 A NO 20100300A NO 20100300 L NO20100300 L NO 20100300L
Authority
NO
Norway
Prior art keywords
menopause
administration
endometrial
loss
uterine cancer
Prior art date
Application number
NO20100300A
Other languages
English (en)
Inventor
Fernand Labrie
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of NO20100300L publication Critical patent/NO20100300L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Det beskrives nye metoder for behandling eller reduksjon av sannsynligheten for å erverve symptomer eller sykdommer på grunn av menopausen hos postmenopausale kvinner, særlig osteoporose, vaginalatrofi og tørrhet, hypogonadisme, redusert libido, hudatrofi, konnektiv vevsykdom, urininkontinens, bryst-, endometrial-, ovarie- og uterincancer, varmetokter, tap av muskelmasse, insulinresistens, tretthet, tap av energi, aldring, fysiske symptomer på menopausen, hos forskjellige varmblodsdyr inkludert mennesker, involvert administrering av en kjønnssteroidforløper. Fremgangsmåten omfatter nye veier for administrering og dosering av dehydroepiandrosteron (DHEA) for å trekke fordel av de positive, androgeniske effekter i vaginalsjiktene lamina propia og/eller sjiktet muscularis, uten og på uønsket måte forårsake systemiske, østrogene effekter for å unngå risikoen for bryst- og uterincancer. Det beskrives videre farmasøytiske preparater for administrering av en eller flere aktive bestanddeler som er nyttige som beskrevet ovenfor.
NO20100300A 2007-08-10 2010-03-04 DHEA-preparater for behandling av menopausen NO20100300L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96427007P 2007-08-10 2007-08-10
US96467307P 2007-08-13 2007-08-13
PCT/CA2008/001444 WO2009021323A1 (en) 2007-08-10 2008-08-08 Dhea compositions for treating menopause

Publications (1)

Publication Number Publication Date
NO20100300L true NO20100300L (no) 2010-04-29

Family

ID=40350317

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20100300A NO20100300L (no) 2007-08-10 2010-03-04 DHEA-preparater for behandling av menopausen

Country Status (28)

Country Link
US (5) US8268806B2 (no)
EP (2) EP2185157B1 (no)
JP (2) JP5725283B2 (no)
KR (3) KR101850125B1 (no)
CN (4) CN109893526A (no)
AR (2) AR068702A1 (no)
AU (1) AU2008286651B2 (no)
BR (1) BRPI0815353A2 (no)
CA (2) CA2820566C (no)
CO (1) CO6260084A2 (no)
DK (1) DK2185157T3 (no)
EA (2) EA020683B1 (no)
EC (1) ECSP10010016A (no)
ES (1) ES2888104T3 (no)
HK (1) HK1217639A1 (no)
IL (1) IL203747A (no)
MA (1) MA31694B1 (no)
MX (1) MX2010001627A (no)
NO (1) NO20100300L (no)
NZ (2) NZ598270A (no)
PE (2) PE20140925A1 (no)
PH (1) PH12013502291B1 (no)
PT (1) PT2185157T (no)
SA (2) SA08290494B1 (no)
SG (3) SG183702A1 (no)
TN (1) TN2010000065A1 (no)
TW (3) TWI609688B (no)
WO (1) WO2009021323A1 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012623A1 (en) * 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
CN106038572A (zh) 2004-10-20 2016-10-26 恩多研究公司 性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
CA2654152A1 (en) 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
US9284345B2 (en) * 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
WO2010118384A2 (en) * 2009-04-10 2010-10-14 Amylin Pharmaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
CA2860133C (en) * 2011-12-29 2016-10-11 Universidad De Chile Vaginal ring comprising dhea or dhea sulphate and optionally a release-modulating agent of the active principle, useful to increase the ovarian reserve in women and to relieve symptoms associated with menopause
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20140045806A1 (en) * 2012-07-25 2014-02-13 Fernand Labrie Sexual arousal, sexual desire, orgasm and/or pleasure following intravaginal prasterone (dhea) administration in women not suffering or independently from dyspareunia or other symptoms of vulvo-vaginal atrophy
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2016018993A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
CA2964371A1 (en) * 2014-10-16 2016-04-21 Gtx, Inc. Methods of treating urological disorders using sarms
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9862101B2 (en) 2015-12-22 2018-01-09 Varian Semiconductor Equipment Associats, Inc. Self-damping end effector
RU2618428C1 (ru) * 2016-03-24 2017-05-03 Общество с ограниченной ответственностью "Научно-производственное предприятие Лаборатория Матрикс" Комплексное косметическое средство
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
CN109350624A (zh) * 2018-05-25 2019-02-19 泓博元生命科技（深圳）有限公司 含有nmn和dhea的女性保健组合物、制剂及其制备方法与应用
CN109364171A (zh) * 2018-05-25 2019-02-22 泓博元生命科技（深圳）有限公司 含有nadh和dhea的卵巢保养组合物、制剂及其制备方法
EP3946594A4 (en) * 2019-03-29 2023-01-04 Martell, Bridget EVA SEGMENTED INTRAVAGINAL RINGS WITH PROGESTERONE
JP6945874B2 (ja) * 2019-12-24 2021-10-06 一般財団法人バイオダイナミックス研究所 経口投与用医薬組成物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
WO2024068968A1 (en) * 2022-09-29 2024-04-04 Rigshospitalet Inhibition of luteinizing hormone (lh) action as treatment of perimenopausal and postmenopausal symptoms and complications

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63104924A (ja) * 1986-10-20 1988-05-10 Kanebo Ltd 膣坐剤
US4835147A (en) 1987-05-06 1989-05-30 City Of Hope Dehydroepiandrosterone therapy for ameleoration of prostate hypertrophy and sexual dysfunction
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5407684A (en) * 1988-12-30 1995-04-18 Virginia Commonwealth University Use of DHEA as a medicinal
US5246704A (en) * 1989-01-23 1993-09-21 Kanebo, Ltd. Vaginal suppository
IE62715B1 (en) 1989-03-10 1995-02-22 Endorecherche Inc Combination therapy for treatment of estrogen sensitive diseases
DE69034035T2 (de) 1989-07-07 2004-01-22 Endorecherche Inc., Ste-Foy Methode zur behandlung androgenbedingter krankheiten
ATE269066T1 (de) 1989-07-07 2004-07-15 Endorech Inc Kombinationstherapie zur prophylaxe und/oder behandlung von gutartiger prostatischer hyperplasie
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
WO1994016709A2 (en) * 1993-01-19 1994-08-04 Endorecherche Inc. Therapeutic uses and delivery systems of dehydroepiandrosterone
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
JP2698865B2 (ja) * 1994-08-08 1998-01-19 仲昭 大澤 筋緊張性ジストロフィー症治療剤
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
US5747059A (en) 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
IL124882A0 (en) 1996-01-11 1999-01-26 Novo Nordisk As Use of 3, 4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
WO1997025034A1 (en) 1996-01-11 1997-07-17 Novo Nordisk A/S Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
SK281737B6 (sk) 1996-04-19 2001-07-10 American Home Products Corporation 2-fenylindolové zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie
US20040014761A1 (en) 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
CA2306837C (en) 1997-10-28 2007-05-08 Asivi, Llc. Treatment of female sexual dysfunction
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US20020099003A1 (en) * 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
US20040044080A1 (en) * 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
US20050070516A1 (en) * 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
US6013665A (en) * 1997-12-16 2000-01-11 Abbott Laboratories Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
ID27922A (id) 1998-06-11 2001-05-03 Endorech Inc KOMPOSISI FARMASETIKAL DAN PENGGUNAAN DARI ANDROST-5-ENA-3β, 17β-DIOL
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) * 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6007824A (en) * 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction
US20030181353A1 (en) * 1998-08-03 2003-09-25 Nyce Jonathan W. Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US7045513B1 (en) * 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
JP5184727B2 (ja) * 1999-06-11 2013-04-17 ワトソン ファーマシューティカルズ， インコーポレイテッド 女性への非経口アンドロゲンステロイドの投与
US6335023B1 (en) * 1999-06-30 2002-01-01 Ruey J. Yu Oligosaccharide aldonic acids and their topical use
US7452545B2 (en) * 2001-11-13 2008-11-18 Yu Ruey J Oligosaccharide aldonic acids and their topical use
US20070042060A1 (en) * 1999-07-01 2007-02-22 Thompson Ronald J Methods to treat one or all of the defined etiologies of female sexual Dysfunction
US20050245494A1 (en) * 1999-07-01 2005-11-03 40 J's Llc Methods to treat one or all of the defined etiologies of female sexual dysfunction
US20020165429A1 (en) * 1999-07-01 2002-11-07 40 J's Llc Clitoral sensitizing arrangements
HU230543B1 (hu) 1999-07-06 2016-11-28 Endorecherche, Inc. Inzulinrezisztencia kezelésére és/vagy megakadályozására szolgáló gyógyszerkészítmények
KR20020073566A (ko) 2000-01-28 2002-09-27 앙도르쉐르슈 인코포레이티드 에스트로겐과 배합된 선택적인 에스트로겐 수용체 조절자
US20020022052A1 (en) * 2000-04-06 2002-02-21 Dransfield Charles William Transdermal delivery system
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
IL145838A (en) * 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
EP1351678A2 (en) * 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
US20070021360A1 (en) 2001-04-24 2007-01-25 Nyce Jonathan W Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase
US20030216329A1 (en) * 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
AU2002303427A1 (en) * 2001-04-24 2002-11-05 East Carolina University Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
AU2002303425A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
AU2002309919B2 (en) 2001-05-16 2008-04-10 Barr Laboratories, Inc. Treatment of conditions relating to hormone deficiencies by administration of progestins
US20030022875A1 (en) 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
FR2828100B1 (fr) 2001-08-02 2004-09-24 Galderma Res & Dev Composition de type emulsion inverse contenant de la dhea et/ou ses precurseurs ou derives, et ses utilisations en cosmetique et en dermatologie
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
US7348352B2 (en) * 2001-10-23 2008-03-25 Bioresponse L.L.C. Diindolylmethane for the treatment of HPV infection
US20040259850A1 (en) * 2001-10-31 2004-12-23 Alves Stephen E. Method for treating or preventing symptoms of hormonal variation including hot flashes
US6824786B2 (en) * 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
EP1492486A2 (en) * 2002-04-10 2005-01-05 Ruey J. Dr. Yu Urea compositions
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US20080206161A1 (en) 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
WO2005066194A1 (en) 2004-01-07 2005-07-21 Endorecherche, Inc. Helix 12 directed steroidal pharmaceutical products
US20050181057A1 (en) * 2004-02-13 2005-08-18 Rosenberg Paul K. Vaginal lubricant
US20060276442A1 (en) * 2004-09-08 2006-12-07 Woodward John R Methods of female sexual enhancement
US20060252734A1 (en) * 2004-09-08 2006-11-09 Woodward John R Methods of female sexual enhancement
US20080119445A1 (en) * 2004-09-08 2008-05-22 Woodward John R Methods of female sexual enhancement
CN106038572A (zh) 2004-10-20 2016-10-26 恩多研究公司 性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
MX2007005098A (es) 2004-11-01 2008-01-16 Endorech Inc Uso de androgenos para reducir la probabilidad de adquirir o tratar el envejecimiento de la piel.
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
JP2009519926A (ja) 2005-12-16 2009-05-21 ライル コーポレート ディベロップメント インコーポレーテッド エストロゲンの非全身性膣投与による膣組織の再生
US8021659B2 (en) * 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
JP4179624B2 (ja) * 2006-07-18 2008-11-12 ヒロセ電機株式会社 平型導体用電気コネクタ
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators

Also Published As

Publication number Publication date
US20130005700A1 (en) 2013-01-03
SG183702A1 (en) 2012-09-27
EP2185157A4 (en) 2010-11-03
TWI388328B (zh) 2013-03-11
SA08290494B1 (ar) 2013-04-20
EA201200369A1 (ru) 2012-09-28
JP5725283B2 (ja) 2015-05-27
ES2888104T3 (es) 2021-12-30
KR20160032257A (ko) 2016-03-23
PH12013502291A1 (en) 2015-09-07
ECSP10010016A (es) 2010-07-30
MX2010001627A (es) 2010-09-14
CA2820566C (en) 2016-09-13
CN105412121A (zh) 2016-03-23
KR101638130B1 (ko) 2016-07-08
SG10201902375XA (en) 2019-04-29
MA31694B1 (fr) 2010-09-01
HK1217639A1 (zh) 2017-01-20
IL203747A (en) 2016-09-29
AR068702A1 (es) 2009-12-02
KR20100061671A (ko) 2010-06-08
US10881650B2 (en) 2021-01-05
WO2009021323A1 (en) 2009-02-19
CA2696127C (en) 2017-06-06
EP2185157B1 (en) 2020-12-16
CA2696127A1 (en) 2009-02-19
US20210069169A1 (en) 2021-03-11
CN102861335A (zh) 2013-01-09
KR101850125B1 (ko) 2018-04-19
AU2008286651A1 (en) 2009-02-19
CO6260084A2 (es) 2011-03-22
AU2008286651B2 (en) 2012-11-22
PE20090945A1 (es) 2009-07-08
EP2441456B1 (en) 2021-10-06
US20120322778A1 (en) 2012-12-20
US8629129B2 (en) 2014-01-14
PT2185157T (pt) 2021-03-15
US8957054B2 (en) 2015-02-17
TWI609688B (zh) 2018-01-01
CN109893526A (zh) 2019-06-18
SA111320726B1 (ar) 2015-08-10
JP6197292B2 (ja) 2017-09-20
DK2185157T3 (da) 2021-03-08
TW201634051A (zh) 2016-10-01
EA020683B1 (ru) 2015-01-30
BRPI0815353A2 (pt) 2015-06-16
US20090054383A1 (en) 2009-02-26
AR114051A2 (es) 2020-07-15
EP2185157A1 (en) 2010-05-19
SG10201601242TA (en) 2016-03-30
JP2010535717A (ja) 2010-11-25
KR101680287B1 (ko) 2016-11-28
PH12013502291B1 (en) 2015-09-07
KR20130103805A (ko) 2013-09-24
NZ583147A (en) 2012-04-27
JP2013060475A (ja) 2013-04-04
CA2820566A1 (en) 2009-02-19
TW200927136A (en) 2009-07-01
PE20140925A1 (es) 2014-08-09
EA201000312A1 (ru) 2010-08-30
EP2441456A1 (en) 2012-04-18
CN101861152A (zh) 2010-10-13
US8268806B2 (en) 2012-09-18
TW201212922A (en) 2012-04-01
NZ598270A (en) 2013-08-30
TN2010000065A1 (en) 2011-09-26
TWI565468B (zh) 2017-01-11
US20120283230A1 (en) 2012-11-08

Similar Documents

Publication Publication Date Title
NO20100300L (no) DHEA-preparater for behandling av menopausen
De Leo et al. Hormonal contraceptives: pharmacology tailored to women's health
US8349820B2 (en) Use of estradiol valerate or 17β-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido
Pavone et al. Aromatase inhibitors for the treatment of endometriosis
Ménard The 45-year story of the development of an anti-aldosterone more specific than spironolactone
Mahady Black Cohosh (Actaea/Cimicifuga racemosa) Review of the clinical data for safety and efficacy in menopausal symptoms
Wiegratz et al. Metabolic and clinical effects of progestogens
Maruo et al. Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas
Moreno-Pérez et al. Clinical practice guidelines for assessment and treatment of transsexualism. SEEN Identity and Sexual Differentiation Group (GIDSEEN)
Egarter et al. Efficacy, tolerability, and rare side effects of tibolone treatment in postmenopausal women
Gupta et al. A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause
Wang et al. The therapeutic effect of dehydroepiandrosterone (DHEA) on vulvovaginal atrophy
JP2013047269A5 (no)
Chawla Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate
Sumino et al. Effects of raloxifene and hormone replacement therapy on forearm skin elasticity in postmenopausal women
Bitzer et al. Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy
Pięta et al. Vaginal dehydroepiandrosterone compared to other methods of treating vaginal and vulvar atrophy associated with menopause
von Holst et al. Efficacy of a new 7-day transdermal sequential estradiol/levonorgestrel patch in women
TR201816243T4 (tr) Aromataz inhibitörlerinin ve antioksidanların kombinasyonları.
UA100701C2 (ru) Композиции dhea для лечения менопаузы
Huang et al. Genistein upregulates placental corticotropin-releasing hormone expression in lipopolysaccharide-sensitized mice
Castelo-Branco et al. Compounds for the treatment of atropic vaginitis
Bahtiar et al. The effect of 70% ethanolic extract of dayak onion bulbs and cowpea on cardiovascular parameters of hypoestrogen model rats
Hernández-Valencia et al. Symptomatic changes in postmenopause with different methods of hormonal therapy
CU20100027A7 (es) Composiciones farmacéuticas

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application